← Eichor
Study identifier: NCT06434766 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Multicenter iTBS Neuromodulation for PTSD Treatment

Condition: Posttraumatic Stress Disorder  ·  Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

PhaseNA
Planned participants140
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex (M1) as adjunct treatment for PTSD patients. The primary outcome measure includes changes in PTSD symptom severity, with secondary outcome measures focusing on negative moods improvements, quality of life and social/occupation functioning and functional connectivity of the brain.

This description comes directly from the study's public registry record.

Talk to the study team

Huiqian Huang, Ph.D.  ·  +8618757143725  ·  hhq0301@zju.edu.cn

Shanshan Li, Bachelor  ·  1252037349@qq.com

Always discuss trial participation with your own doctor first.

Locations (5)

Shanghai Mental Health CenterShanghai, Shanghai Municipality, ChinaRecruiting
First Affiliated Hospital of Anhui Medical UniversityHangzhou, Zhejiang, ChinaRecruiting
Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, Zhejiang, ChinaRecruiting
The Affiliated Kangning Hospital of Ningbo UniversityNingbo, Zhejiang, ChinaRecruiting
Tongji Hospital of Tongji UniversityShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06434766